PGY2 Specialized Residency: Oncology
Positions for 2023-24 have been filled with early commitments.
The Post Graduate Year 2 (PGY2) specialized residency program in oncology is designed to develop clinical pharmacy specialists equipped with the expertise and clinical aptitude for practice in acute and ambulatory oncology settings.
The PGY2 Oncology Pharmacy Residency is an American Society of Health System Pharmacists (ASHP) accredited residency program. PGY2 residents receive training in hematologic and solid cancers, symptom management, oncology pharmacy administration, and investigational therapeutics at the UCSF Helen Diller Family Comprehensive Cancer Center. Over 100,000 cancer patient visits occur annually across our three San Francisco campuses: Parnassus Heights, Mt. Zion, and Mission Bay. As a large clinical research institution, UCSF has over 350 active cancer clinical trials open at any given time. Residents will work in an interdisciplinary environment to optimize oncology pharmaceutical care and influence clinical outcomes for cancer patients. Required, longitudinal, and elective learning experiences in various oncology settings will enable the resident to cultivate problem-solving skills, work collaboratively with other healthcare professionals, and function independently as an oncology pharmacy practitioner. Teaching is also an integral component of the program as UCSF Health is closely affiliated with the UCSF School of Pharmacy. The resident will have the opportunity to teach Doctor of Pharmacy students in core curriculum oncology and infectious disease courses, and will precept students and PGY1 residents on different rotations.
All residents receive orientation and training in July before embarking on clinical rotations. Rotation blocks are 4-5 weeks in duration, for a total of 9 blocks throughout the residency year. All residents will be assigned 8 core blocks, and may select 1 elective learning experience. Longitudinal clinics are scheduled as two blocks that are approximately 3-4 months in length. Longitudinal administrative responsibilities and committee work extend throughout the year. Residents receive 2 weeks of research time in late December.
Sequencing of Learning Experiences
The PGY2 oncology resident receives orientation to oncology specific activities and operations in the first month of the program. Core rotational learning experiences are scheduled prior to elective courses. The oncology resident will be exposed to a broad range of supportive care topics, chemotherapy and immunotherapy, and other treatment modalities employed in the treatment of different malignancies. Elective rotations will supplement the resident’s professional interests. Longitudinal learning experiences in administration, research and teaching will fortify the resident’s understanding of different facets of oncology pharmacy seen within the healthcare system.
- Inpatient Malignant Hematology (5 weeks)
- Inpatient BMT/Cellular Therapy (5 weeks)
- Inpatient Medical Oncology (4 weeks)
- Ambulatory Malignant Hematology/BMT/Cellular Therapies Clinic (5 weeks)
- Ambulatory Breast, Melanoma, Head and Neck Oncology Clinics (4 weeks)
- Ambulatory Gastrointestinal and Gynecology Oncology Clinics (4 weeks)
- Ambulatory Genitourinary and Thoracic Oncology Clinics (5 weeks)
- Investigational Drug Services (4 weeks)
- Oncology Practice Administration
- (MUE, P&T monograph, QI project, Medication Safety Evaluation)
- Oncology Roundtable Weekly Discussion (supportive care, disease states)
- Oncology Operations
Longitudinal Clinical Rotations (2)
- Oral Oncolytic/Specialty Pharmacy Service (1/2 day for 3-4 months)
- Symptom Management Clinic (1/2 day clinic for 3-4 months)
- Immunocompromised Infectious Disease Service
- Pediatric Blood and Marrow Transplantation
- Pediatric Hematology/Oncology
- Investigational Drugs (Malignant Hematology)
- Benign Hematology
- Any rotation offered as a required experience
- Off-site oncology practice
All oncology residents receive comprehensive training in the inpatient chemotherapy and outpatient infusion center areas during the orientation block, including formalized training in sterile compounding, aseptic technique, and hazardous drug compounding.
Operational staffing occurs longitudinally and takes place approximately every third weekend spanning throughout the residency year. This is inclusive of 1 major holiday and 2 minor holiday weekends. PGY2 Oncology Pharmacy residents staff in 2 areas – the inpatient chemotherapy pharmacy at Parnassus and the outpatient infusion center at Parnassus.
All projects are of a scope suitable for publication. The oncology residents receive project proposal submissions from the oncology pharmacy preceptors and faculty for considerations as a research project. Projects are rigorously reviewed for feasibility and appropriateness of timeline for the resident research process by residency leadership. The list developed in this forum revolve around clinical outcomes in the management of hematology/oncology patients, the value of clinical pharmacist services, and/or focus on quality improvement initiatives such as drug safety, optimal medication use and cost effective drug use. The vetted projects are presented to the oncology residents during orientation for consideration. Residents rank the research projects based on interest prior to selection and assignment by the Residency Program Director.
PGY2 oncology residents participate in the UCSF Research Certificate Program and will gain skills in: adhering to a research timeline, creating an appropriate study design and methodology, completing data collection and analysis and summarizing research findings. Residents are enrolled in the Designing Clinical Research course that is part of the Summer Clinical Research Workshop. This interprofessional curriculum within the Department of Epidemiology & Biostatistics guides residents through modification of their research proposal and creation of a version suitable for submission to the UCSF Institutional Review Board. For projects requiring more advanced statistics, residents also receive support to work with the Clinical and Translational Science Institute (CTSI) in order to complete analysis.
Poster & Platform Presentations
All projects are of a scope suitable for publication. Residents will provide a platform presentation of their research in the early spring at the Northern California Oncology Pharmacy Network Annual Residency Forum. Projects are presented as posters at the Hematology/Oncology Pharmacy Association annual meeting and at the University of California Pharmacy Collaborative Conference. Posters are also presented at the Vizient Pharmacy Network Poster session that precedes the ASHP Midyear Clinical Meeting.
Resident Research Projects
|Francesca Alcala (2023)||Impact of removing granulocyte colony stimulating factors on hematopoietic allogeneic stem cell transplant outcomes|
|Maher Alhaja (2023)||Cardiac Safety of Pegylated Liposomal Doxorubicin after Conventional Doxorubicin Exposure in Sarcomas and Breast Cancer Patients|
|Nancy Chukwumezie (2023)||Identifying Risk Factors for Hypersensitivity Reactions to Pegylated-Liposomal Doxorubicin|
|Tiffany Guan (2022)||
Evaluation of Direct Oral Anticoagulants vs Low-Molecular Weight Heparins for Venous Thromboembolism Treatment in Patients with Gastrointestinal Malignancies
|Carolyn Rath (2022)||Evaluation of Maintenance Lenalidomide in Patients with Multiple Myeloma after Autologous Stem Cell Transplant|
|Kim Vo (2022)||Evaluation of Biomolecular Markers for Response in PD-1/PD-L1 Inhibitors in the Treatment of Hepatocellular Carcinoma|
Angela Lee (2021)
|Characterization of Infections and GVHD Outcomes in Patients Receiving Ruxolitinib or Ibrutinib for GVHD|
|Karen Shin (2021)||Immunotherapy Response Based on Sex in Melanoma Patients|
|Andrew Tam (2021)||Comparing treatment outcomes in older acute leukemia patients who receive younger haploidentical stem cell transplant (HCT) vs. older matched related/unrelated HCT (AGE-ALTER)|
Shannon Jeong (2020)
|Use of Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evaluation of Molecular Drivers and Mutations|
|Edna Miao (2020)||Characterizing CMV Disease in Adult Allogeneic Transplant Recipient at UCSF Medical Center|
|Felice Wu (2020)||
Menopause status and Immunotherapy Response in Melanoma Patients (PRISM)
Edna Cheung (2019)
Denosumab frequency to Optimize Skeletal Events in Metastatic Oncology Patients (DOSE-MOP)
Sarah Leverett (2019)
Retrospective, single-institution study of PD-1/PD-L1 inhibitors in second line metastatic bladder cancer
Sammi Tam (2019)
Update on efficacy of the modified Linker regimen (UCSF 8707) in newly diagnosed acute lymphoid leukemia patients
Dorothy Wang (2018)
Evaluation of the efficacy and toxicity of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia
Wendy Yuen (2018)
A retrospective comparison of fixed-dose-rate (FDR) versus standard infusion gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of metastatic pancreatic cancer
Katie Dacey (2017)
Incidence of immune-related adverse events with PD-1 inhibitors based on prior CTLA-4 inhibitor exposure in patients with melanoma
Sarah Kim (2017)
Hyper-CAD plus Bortezomib or Carfilzomib for Relapsed/Refractory Multiple Myeloma Patients: A Comparison of Response Rates and Toxicity
Vivian Loo (2016)
Evaluation of docetaxel dose intensity in overweight metastatic prostate cancer patients
Kathryn Yee (2016)
Tolerability of Lenalidomide Maintenance Therapy in Multiple Myeloma Patients Post-Autologous Stem Cell Transplant
Hue Nguyen (2015)
Toxicity and Outcomes Associated with L-asparaginase versus PEG-asparaginase in the Linker Regimen for Adult Patients with Acute Lymphoblastic Leukemia
Marisela Tan (2015)
Retrospective review of Pertuzumab, Trastuzumab, Taxane combination versus Ado-trastuzumab Emtansine monotherapy in trastuzumab-experienced HER2 positive advanced breast cancer
Bao Dao (2014)
Evaluation of Combination Pertuzumab, Trastuzumab, and Taxane for Metastatic Breast Cancer After First Progression
|Son Ho (2014)||
The incidence and risk factors associated with thromboembolic events among patients with CNS lymphoma
Teaching is a focus of the residency at UCSF, and residents receive a Teaching Certificate upon program completion if they complete the required elements of the program. The certificate recognizes the significant contributions and skills that are attained during the residency year. Residents receive training in teaching methodology, precepting and small group conference facilitation through a variety of educational seminars that are planned during the year.
Teaching opportunities may include the following:
- Large group teaching
- Oncology Therapeutics Lecture (School of Pharmacy)
- Continuing Pharmacy Education, UCSF Health
- Regional Journal Club/Case Presentation (Northern California Oncology Pharmacy Network)
- Interprofessional education
- Rotation based in-service presentations to nursing and provider staff
- Small group facilitation
- Conference leader in the Oncology & Infectious Disease Therapeutics courses (School of Pharmacy)
- Conducting an OSCE exam (School of Pharmacy)
- Precepting IPPE and APPE students on clinical rotations and project-based work
Salary & Benefits
$63,525 annually, paid biweekly
Medical/Dental/Vision Plan and Professional Liability Insurance
Vacation / Professional / Sick leave
All residents will receive 10 days of paid vacation, and 10 days of paid professional leave. Professional leave may be used to attend professional meetings, and for post-graduate or professional job interviews. Additionally, all residents will receive up to 12 days of paid sick leave per academic year.
All residents are provided with a stipend to support travel, lodging, and registration fees for the purposes of professional conferences. The amount of the travel stipend is determined each year and may not cover all travel expenses.
Residents will be provided with a UCSF white coat, scrubs and access to the resident office workspace. Meal cards are provided with a value determined by the number of staffing hours assigned.
July 5, 2023 to July 12, 2024
PGY2 Oncology (NMS 512060) – *2023-24 positions have been filled with early commitments*
The Residency Program Director and residents recruit potential residency applicants at the following events:
- American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting
- Residency Showcase
- Personnel Placement Services (PPS)
- Participation at PPS is highly encouraged
Requirements for Admission
Applicants must be a graduate of an ACPE-accredited college of pharmacy or otherwise be eligible for licensure in California. Additionally, applicants must be participating in, or have completed, an ASHP-accredited PGY1 pharmacy residency program or one in the ASHP accreditation process (i.e., one with candidate or preliminary accreditation status).
Non-US and US Citizens from Foreign Schools of Pharmacy
Non-US citizens must be eligible to work and live in the US by obtaining an appropriate visa and must be eligible to work as a licensed pharmacist in California. We do not sponsor visas for foreign pharmacy residency applicants. Non-US and US citizens who graduate from a foreign school of pharmacy must first be certified by examination before the process of licensure in the US can begin. The Foreign Pharmacy Graduate Equivalency Committee ™ (FPGEC®) certificate program operates under the auspices of the National Association of Boards of Pharmacy®. The NABP® provides the FPGEC Certification Program as a means of documenting the educational equivalency of a candidate's foreign education, as well as the license and or registration to practice pharmacy. More information about this entire process is provided in these NABP® links: nabp.pharmacy.
How to Apply
- Match: All applicants must register for The Match – ASHP Resident Matching Program.
- PhORCAS: Applications will be accepted through PhORCAS (Pharmacy Online Residency Centralized Application Service), a web-based pharmacy residency application system. The application deadline is Saturday, December 31st, 2022.
- Cover Letter: A cover letter describing the elements of the program that most interest you and how each element relates to your personal goals is also required.
- Letters of Recommendation: We request a minimum of one (two is preferred) of your three references should come from a preceptor who you have worked as a resident within a clinical setting, related to an experience in acute or ambulatory care. The clinical preceptor should be able to comment on your scope of responsibility, total patient load, level of autonomy, clinical abilities, and organizational and time management skills. All 3-reference writers should use the standard PhORCAS template to submit their candidate recommendation and comment on a minimum of 7 of the 13 listed candidate characteristics.
Each PGY2 applicant packet is screened and scored by 3 preceptors in the oncology pharmacy residency program. Screeners assess the following: communication skills, clinical experience (breadth, performance, scope of activity), personal/environmental factors (maturity, confidence, motivation, and adaptability), and work experience, aggregate letters of recommendation, leadership/initiative, teaching (interest and/or experience), research (interest and/or experience), teaching (interest and/or experience), extracurricular involvement and academic performance. The screening score is used to determine if an interview will be granted.
The interview is a day-long engagement involving activities with preceptors from both Parnassus Heights and Mission Bay campuses. The interview process consists of two 45-minute panel interviews, and a personal interview with the Residency Program Director. Applicants are asked to prepare in advance a 15-minute presentation on an oncology-related topic of their choice.
PGY2 Oncology interviews will be held in late January and through February for the upcoming interview cycle.
Richard Fong, PharmD, BCOP
Residency Program Director, PGY2 Oncology
Senior Pharmacy Supervisor - Hematology/Oncology/BMT, UCSF Health
Associate Clinical Professor, UCSF School of Pharmacy
505 Parnassus Ave, M39C, Box 0312
San Francisco CA 94143
Laura Quintal, PharmD, BCOP
Residency Program Coordinator - Mission Bay campus, PGY2 Oncology
Investigational Drug Services Pharmacist, UCSF Health
Assistant Clinical Professor, UCSF School of Pharmacy
1825 4th Street, Room L3113
San Francisco CA 94158
Marisela Tan Banez, PharmD, BCOP, BCPS
Residency Program Coordinator - Parnassus campus, PGY2 Oncology
Hematologic Malignancies & BMT Clinical Pharmacist, UCSF Health
Associate Clinical Professor, UCSF School of Pharmacy
505 Parnassus Ave, M39C, Box 0312
San Francisco CA 94143